Revenio Group Oyj
Sector unknown·REG1V · Nasdaq Helsinki·Fiscal year to 31/12/2025
Exposure profile
Derived from what the company itself writes. Empty directions mean the report doesn't mention themes of that type.
In their own words
Grouped by theme, from the management review in the annual report. A · The company itself is a verbatim quote, B · From the report is without a verified quote.
Artificial intelligence
Technology
DriverNegative impact: weakens
“Another strategic risk is related to the ability to shift the strategic focus towards integrated and predictive eye care pathways and to succeed in R&D activities and to maintain a competitive product mix.”
Annual report 2025A · The company itself
StrategyPositive impact: strengthens
“During the 2024–2026 strategy period, Revenio’s primary objective is to improve the quality of clinical diagnostics and enhance care pathways through product innovation as well as software and AI-driven solutions.”
Annual report 2025A · The company itself
StrategyPositive impact: strengthens
“The Group is developing new solutions to support the screening, prevention and diagnosis of eye diseases. As the prevalence of vision-threatening diseases increases, the focus is shifting toward integrated and preventive eye care.”
Annual report 2025A · The company itself
StrategyPositive impact: strengthens
“Artificial intelligence is becoming a key factor in the transformation of eye care, with the growing need for care and the simultaneous shortage of professionals calling for more efficient solutions. The AI-powered screening and software solutions facilitate the efficient processing of large patient volumes, support clinical decision-making and help to allocate scarce expert resources to the most demanding cases.”
Annual report 2025A · The company itself
StrategyPositive impact: strengthens
“The comprehensive approach that merges hardware, software and AI into seamless end-to-end solutions and leverages the company’s extensive AI partner network, supports the efficiency of care pathways, improves the quality of diagnostics and allows to build scalable and sustainable business models globally.”
Annual report 2025A · The company itself
Market
“During the financial year, we started sales of the new iCare MAIA microperimeter and launched the cloud-based iCare ALTIUS eye health information management solution in the United States.”
Annual report 2025A · The company itself
Market
“Net sales generated by software solutions increased significantly and the number of customer sites using iCare ILLUME was already nearly 350 in Europe and measurement volumes more than doubled year-on-year.”
Annual report 2025A · The company itself
Market
“The screening solution supports the early detection of eye diseases and strengthens the clinical effectiveness of the screening process. The company’s distribution network expanded, particularly in EMEA and LATAM, and it won new national screening programs in the Middle East and Central and Northern Europe, among others.”
Annual report 2025A · The company itself
Chains out: this strengthens Data centres, strengthens Semiconductors and electronic components, strengthens Semiconductor industry
Digitalisation
Technology
DriverNegative impact: weakens
“Another strategic risk is related to the ability to shift the strategic focus towards integrated and predictive eye care pathways and to succeed in R&D activities and to maintain a competitive product mix.”
Annual report 2025A · The company itself
StrategyPositive impact: strengthens
“During the 2024–2026 strategy period, Revenio’s primary objective is to improve the quality of clinical diagnostics and enhance care pathways through product innovation as well as software and AI-driven solutions.”
Annual report 2025A · The company itself
StrategyPositive impact: strengthens
“The comprehensive approach that merges hardware, software and AI into seamless end-to-end solutions and leverages the company’s extensive AI partner network, supports the efficiency of care pathways, improves the quality of diagnostics and allows to build scalable and sustainable business models globally.”
Annual report 2025A · The company itself
StrategyPositive impact: strengthens
“The software solutions are designed to seamlessly integrate with wider eye care ecosystems.”
Annual report 2025A · The company itself
Chains in: Cybersecurity (products and services) strengthens, Public investment and infrastructure strengthens
Chains out: this strengthens IT consulting and public-sector IT
Medical devices
Technology
Market
“Sales of intraocular pressure measuring devices, or tonometers, were good during 2025. In particular, sales of the iCare IC200 tonometer were strong during 2025. iCare HOME2 tonometer performed well. iCare TONOVET Pro and iCare TONOVET Pet for veterinary use performed very strongly during 2025.”
Annual report 2025A · The company itself
Market
“In fundus imaging devices, iCare DRSplus in particular, performed strongly during 2025.”
Annual report 2025A · The company itself
Market
“During the financial year, we started sales of the new iCare MAIA microperimeter and launched the cloud-based iCare ALTIUS eye health information management solution in the United States.”
Annual report 2025A · The company itself
Market
“Sales of the iCare MAIA microperimeter performed well in the final quarter of the year, and the device’s reception in the market has been extremely promising.”
Annual report 2025A · The company itself
Chains in: Ageing population strengthens
Ageing population
Geography
DriverPositive impact: strengthens
“The global need for eye care is increasing as populations age, lifestyle related diseases such as diabetes become more prevalent.”
Annual report 2025A · The company itself
Chains out: this strengthens Healthcare and hospitals, strengthens Medical devices, strengthens Hearing aids and hearing care
Diabetes care
Technology
DriverPositive impact: strengthens
“The global need for eye care is increasing as populations age, lifestyle related diseases such as diabetes become more prevalent.”
Annual report 2025A · The company itself
Business cycle and GDP growth
Macro
DriverNegative impact: weakens
“Economic and political uncertainties, interest and inflation risks and the unstable trade and geopolitical situation may affect the demand for Revenio Group products.”
Annual report 2025A · The company itself
Chains out: this strengthens Global trade volumes, strengthens Construction
Cybersecurity (products and services)
Technology
DriverNegative impact: weakens
“Possible causes for reputational damage include cyber security or compliance challenges or notable delivery or product quality issues. Leakage of sensitive employee or customer data might also lead to reputational damage and notable financial consequences.”
Annual report 2025A · The company itself
Chains in: Cyber attacks and IT security risk strengthens
Chains out: this strengthens Digitalisation
Geopolitical uncertainty
Macro
DriverNegative impact: weakens
“Economic and political uncertainties, interest and inflation risks and the unstable trade and geopolitical situation may affect the demand for Revenio Group products.”
Annual report 2025A · The company itself
Chains out: this strengthens Defence budgets, strengthens Energy security, strengthens Tariffs and trade policy, weakens Global trade volumes, strengthens Sea freight and freight rates, weakens Reconstruction of Ukraine
M&A and consolidation
Macro
DriverPositive impact: strengthens
“In parallel, the eye care industry is undergoing consolidation, which is an important structural trend shaping the future development of the sector.”
Annual report 2025A · The company itself
Pandemics and outbreaks
Macro
DriverNegative impact: weakens
“Moreover, global pandemics could have direct and indirect effects on Revenio Group's business, including and an increased risk of personnel being incapacitated. Government-mandated closures of factories or borders may weaken Revenio Group's operating environment and restrictions on the movement of people could hamper the sales and delivery of Revenio’s products.”
Annual report 2025A · The company itself
Chains out: this weakens Aviation and travel, strengthens Vaccines (travel health and preparedness)
USD vs DKK/EUR
Macro
DriverNegative impact: weakens
“Changes in the USD/EUR exchange rate had a negative impact on net sales and profit in 2025.”
Annual report 2025A · The company itself
Chains out: this mixed effect United States
Competitors mentioned in the report
No named competitors in the report.
Financial figures
| Revenue latest fiscal year | 0.11 bn EUR |
| Revenue growth vs. the year before, same method | 6 % |
| EBITDA reported by the company | 0.03 bn EUR |
| Net debt debt incl. leasing minus cash | Net cash 0.02 bn EUR |
| Diluted EPS per share | N/A |
Source: annual report (ESEF) A. See the report
Criteria
| Profit | N/A |
| Growing | ✓ |
| Healthy balance sheet | ✓ |
Only the criteria that can be computed from financial statements on this page. The remaining criteria (such as price and dividend) need a share price and are in the analysis.
Figures are in the report's currency (EUR), not converted to DKK. Quotes are shown as the company's own words in the report's original language.